Jeena Sikho Lifecare Limited
NSE: JSLLWellness
Share price
₹381.25
-8.62% close of 8 Oct 2026
Business score
How strong the business is, in one number. The parts behind it are in Pro.
74
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹4,766 Cr
P/E ratio
20.1
P/B ratio
10.1
ROCE
64.4%
ROE
61.4%
Dividend yield
1.1%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 56.7% over the past year, and 52.5% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 34.7% to 42.8% over the last year.
Whether it grew faster than its sector
It grew 52.5% a year against a sector median of 13.9% — 38.5 percentage points faster.
Room to re-rate, or risk of de-rating
At 20.1× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 83.9×, across 3 companies. It is against its own five-year median of 99.4×, the 0th percentile of its own range.
Whether growth justifies the valuation
Priced at 0.2 times its growth rate, on earnings growth of 88%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Jeena Sikho Lifecare Limited — this one | 88%/yr | 20.1× | ₹0.23 |
| ETERNAL LIMITED | 28%/yr | — | — |
| Avenue Supermarts Limited | 8%/yr | 76.4× | ₹9.6 |
| Trent Limited | 71%/yr | 83.9× | ₹1.2 |
| Lenskart Solutions Limited | 110%/yr | 172.4× | — |
| Meesho Limited | 6%/yr | — | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies across the whole Consumer Services sector, it ranks 1 of 130 on returns, 7 of 120 on growth, 11 of 129 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 64.4% on capital, ahead of 99% of companies across its whole sector. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the 4 years of cash statements on file it made ₹369 crore of cash from the business, spent ₹120 crore on plant and equipment, and returned ₹38 crore to lenders and shareholders.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
8 of 9 checks clear · 89%
Latest result · Q2 FY26
What the last results showed. Whether management kept its word is in Pro.
Announced 1 Sep 2026 · Standalone · Unaudited
Revenue
₹190 Cr
Net profit
₹59 Cr
EPS
₹4.73
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹4,766 Cr
- Prev close
- ₹381.25
- 52w High
- ₹835
- 52w Low
- ₹378
- Enterprise value
- ₹4,689 Cr
- Beta
- 1.4
- Price CAGR 1y
- -46.0%
- Price CAGR 3y
- 49.0%
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 32.9%
- PEG ratio
- 0.2
- P/E ratio
- 20.1
- P/B ratio
- 10.1
- EV / EBITDA
- 12.9
- Industry P/E
- 30.9
- ROCE
- 64.4%
- ROCE 5y average
- 58.0%
- ROE
- 61.4%
- Debt / Equity
- 0.3
- Interest coverage
- 22.2
- Dividend yield
- 1.1%
- ROE 3y average
- —
- ROE last year
- 61.0%
Annual P&L
- Annual revenue
- ₹801 Cr
- Annual profit
- ₹222 Cr
- Operating margin
- 44.0%
- Net profit margin
- 27.7%
- EBITDA margin
- 43.8%
- Sales growth 3y
- 76.0%
- Sales growth 5y
- —
- Profit growth 3y
- 88.0%
- Profit growth 5y
- —
- EPS
- ₹17.8
- Sales growth TTM
- 57.0%
- Profit growth TTM
- 103.0%
- Dividend payout
- 25.0%
Quarter P&L
- Sales latest quarter
- ₹224 Cr
- Profit latest quarter
- ₹66 Cr
- YoY quarterly sales growth
- 28.8%
- YoY quarterly profit growth
- 29.4%
- OPM latest quarter
- 41.0%
Balance Sheet
- Book Value
- ₹37.4
- Face Value
- ₹2.0
- Total debt
- ₹127 Cr
- Total cash
- ₹109 Cr
- Borrowings
- ₹127 Cr
- Reserves / Equity
- 17.7
Cash Flow
- Operating cash flow
- ₹254 Cr
- Free cash flow
- ₹221 Cr
- FCF yield
- 4.3%
- Net cash flow
- -₹7 Cr
Shareholding
- Promoter holding
- 63.6%
- FII holding
- 4.8%
- DII holding
- 0.4%
- Public holding
- 31.2%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Jeena Sikho | 417.20 | 21.9 | 5,186 | 1.08 | 65.9 | 28.6 | 224.4 | 28.8 | 64.4 |
| Kaya Ltd | 310.00 | 471 | 0.00 | -27.8 | -182.3 | 55.8 | 2.0 | -45.6 | |
| Lloyds Luxuries | 59.50 | 144 | 0.00 | 0.4 | 107.5 | 33.2 | 36.4 | -4.3 | |
| Quanto Agroworld | 63.90 | 13.3 | 112 | 0.00 | 4.4 | 11.3 | 25.6 | ||
| Median | 186.95 | 17.6 | 307 | 0.00 | 2.4 | 28.6 | 44.5 | 28.8 | 10.7 |
Competes with: Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Kaya Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 71 | 75 | 87 | 118 | 114 | 116 | 139 | 174 | 190 | 222 | 216 | 224 |
| Expenses | 74 | 86 | 93 | 96 | 98 | 121 | 138 | 132 | |||||
| Material Cost | 0 | 0 | 0 | 0 | 0 | ||||||||
| Change in Inventories | -2.54 | -1.52 | -1.82 | -2.78 | -1.38 | ||||||||
| Purchases of Stock-in-Trade | 14 | 26 | 26 | 28 | 27 | ||||||||
| Employee Cost | 30 | 33 | 39 | 46 | 44 | ||||||||
| Other Expenses | 54 | 41 | 57 | 67 | 62 | ||||||||
| Operating Profit | 40 | 30 | 46 | 79 | 92 | 101 | 78 | 92 | |||||
| OPM % | 12 | 13 | 12 | 18 | 25 | 35 | 26 | 33 | 45 | 48 | 45 | 36 | 41 |
| Other Income | 3 | 0 | 0 | 1 | 1 | 3 | 3 | 14 | |||||
| Exceptional items (within Other Income) | 0 | 0 | 0 | 0 | 0 | ||||||||
| Interest | 2 | 4 | 3 | 2 | 4 | 3 | 4 | 3 | |||||
| Depreciation | 6 | 8 | 9 | 10 | 10 | 11 | 16 | 15 | |||||
| Profit before tax | 35 | 18 | 34 | 69 | 79 | 89 | 61 | 88 | |||||
| Tax % | 25 | 26 | 25 | 25 | 25 | 25 | 26 | 25 | |||||
| Net Profit | 27 | 13 | 25 | 51 | 59 | 67 | 45 | 66 | |||||
| EPS in Rs | 2.14 | 1.06 | 2.04 | 4.13 | 4.73 | 5.36 | 3.63 | 5.31 | |||||
| Diluted EPS in Rs | 4.12 | 4.72 | 5.35 | 3.62 | 5.29 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 147 | 205 | 469 | 801 | 851 |
| Expenses | 128 | 159 | 328 | 451 | 489 |
| Material Cost | 0 | ||||
| Change in Inventories | -8.67 | ||||
| Purchases of Stock-in-Trade | 100 | ||||
| Employee Cost | 148 | ||||
| Other Expenses | 212 | ||||
| Operating Profit | 18 | 46 | 141 | 351 | 363 |
| OPM % | 12 | 22 | 30 | 44 | 43 |
| Other Income | 1 | 3 | 7 | 8 | 22 |
| Exceptional items (within Other Income) | 0 | ||||
| Interest | 1 | 1 | 11 | 14 | 15 |
| Depreciation | 3 | 3 | 29 | 48 | 53 |
| Profit before tax | 15 | 44 | 108 | 297 | 316 |
| Tax % | 26 | 24 | 26 | 25 | |
| Net Profit | 11 | 34 | 80 | 222 | 236 |
| EPS in Rs | 1.23 | 2.72 | 6.43 | 18 | 19 |
| Diluted EPS in Rs | 18 | ||||
| Dividend Payout % | -0 | 8 | 17 | 25 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- —
- 3 years
- 76%
- TTM
- 57%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- 88%
- TTM
- 103%
Stock price CAGR
- 10 years
- —
- 5 years
- —
- 3 years
- 49%
- 1 year
- -46%
Return on equity
- 10 years
- —
- 5 years
- —
- 3 years
- —
- Last year
- 61%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 14 | 25 | 25 |
| Reserves | 26 | 112 | 231 | 442 |
| Borrowings | 7 | 1 | 117 | 127 |
| Other Liabilities | 18 | 24 | 46 | 80 |
| Minority Interest | -0.13 | |||
| Total Liabilities | 62 | 151 | 419 | 674 |
| Fixed Assets | 29 | 60 | 253 | 293 |
| CWIP | 5 | 1 | 13 | 3 |
| Investments | -0 | 5 | 4 | 110 |
| Other Assets | 28 | 86 | 149 | 269 |
| Total Assets | 62 | 151 | 419 | 674 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from Operating Activity | 16 | 15 | 84 | 254 |
| Cash from Investing Activity | -18 | -33 | -64 | -202 |
| Cash from Financing Activity | -5 | 48 | -22 | -59 |
| Net Cash Flow | -7 | 29 | -2 | -7 |
| Free Cash Flow | -2 | -15 | 45 | 221 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 23 | 39 | 66 | 32 |
| Inventory Days | 149 | 85 | 78 | 81 |
| Days Payable | 109 | 126 | 106 | 92 |
| Cash Conversion Cycle | 62 | -1 | 38 | 20 |
| Working Capital Days | -12 | 28 | 28 | 15 |
| ROCE % | 52 | 64 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
company capacity utilisation %
59.00pct
2026-06-30
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
-77.12inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
18,64,030inr
2026-03-31
volume growth %
10.00pct
2026-06-30
News
News and filings about Jeena Sikho Lifecare Limited. Open one to see why it matters.
21 Sept, 20:18 IST · Company event · low impact
Jeena Sikho Lifecare Limited — launch of new Products.
5 Sept, 18:05 IST · Company event · low impact
Jeena Sikho Lifecare Limited — Launch of new products
3 Sept, 18:05 IST · Company event · low impact
Jeena Sikho Lifecare Limited — Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Launch of New Products
26 Aug, 18:05 IST · Company event · low impact
Jeena Sikho Lifecare Limited — Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Launch of New Products.
13 Aug, 18:05 IST · Company event · medium impact
Jeena Sikho Lifecare Limited — Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Proposal for Establishment of a New Hospital Facility at Bareilly, Uttar Pradesh.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- finished / contract-manufactured Ayurvedic products purchased as stock-in-trade (Shuddhi brand)
Depends on the price of
- Medicinal Herbs
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Consumer Services
- Industry
- Wellness
- Classification
- Consumer Services › Wellness
- ISIN
- INE0J5801029
Business segments
- Ayurvedic products/ medicines · 52%
- Ayurvedic healthcare services · 48%
- Others · 0%
News impact
Big market events that reach Jeena Sikho Lifecare Limited, and how the effect spreads.
No recent market events reach this company.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 21 Sep 2026 | unspecified | ₹4.5 |
|---|---|---|
| 22 Sep 2025 | unspecified | ₹1.1 |
Splits, bonuses & buybacks
- daily-prices repair: 8 rows from NSE's archive (replace 2, delete 1, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 7 Oct 2026 | OREGANO LIFE PRIVATE LIMITED | SELL | 6,98,490 | ₹420.28 |
| 4 Jun 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | BUY | 11,94,153 | ₹691.78 |
| 4 Jun 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | SELL | 11,88,446 | ₹692.12 |
| 4 Jun 2026 | QE SECURITIES LLP | BUY | 10,64,305 | ₹689.75 |
| 4 Jun 2026 | MICROCURVES TRADING PRIVATE LIMITED | BUY | 10,62,030 | ₹689.33 |
| 4 Jun 2026 | MICROCURVES TRADING PRIVATE LIMITED | SELL | 10,62,030 | ₹689.58 |
| 4 Jun 2026 | QE SECURITIES LLP | SELL | 10,22,436 | ₹692.57 |
| 4 Jun 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | SELL | 8,12,684 | ₹695.43 |
| 4 Jun 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | BUY | 8,12,684 | ₹695.13 |
| 4 Jun 2026 | HRTI PRIVATE LIMITED | BUY | 7,94,461 | ₹688.22 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call10 Aug 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY262 Jun 2026
- Earnings call · Q3FY269 Feb 2026
- Annual report · 2024-253 Sep 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.